The White House Office of Management and Budget is reviewing a notice expected to be part of the president’s April 26 announcement of a plan to lower drug costs, and lobbyists are taking the review as a sign the plan will ask for feedback on either Medicare Part D rebates or Part B policies. Lobbyists and consultants said there are clues among the sparse information in the OMB listing. It’s a notice, not a rule, which indicates this is the...